ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • 2026 ACR/ARP PRSYM
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Cohort Study"

  • Abstract Number: LB16 • ACR Convergence 2025

    Mepolizumab Reduces End-Organ Manifestations Compared with Standard of Care in Patients with EGPA and HES: A US Real-world Analysis

    David Silverman1, Timothy Barnes2, Nnaemeka Odo2, Jared Silver3, Lisa Le2, Amy Edgecomb4 and Hitesh Patel5, 1Rheumatology Department, Kaiser Permanente Colorado Medical Group, Denver, Colorado, 2Value and Evidence Solutions, Optum Life Sciences, Eden Prairie, Minnesota, 3Clinical Development, Amgen, Thousand Oaks, California, 4Anti-infectives and Respiratory, GSK, Philadelphia, Pennsylvania, 5US Medical Affairs, GSK, Durham, North Carolina

    Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) and hypereosinophilic syndrome (HES) are rare systemic diseases characterized by persistent eosinophilia and tissue infiltration, resulting in end-organ dysfunction…
  • Abstract Number: 0300 • ACR Convergence 2025

    Exploring Malignancy in Anti-synthetase Syndrome: A Multisite Retrospective Study

    Reena Yaman1, Archit Srivastava2, Alejandro Arango Martinez3, Caroyln Harvey4, Ronald Butendieck5, Vikas Majithia6 and Florentina Berianu1, 1Mayo Clinic Florida, Jacksonville, FL, 2Mayo Clinic, Florida, Jacksonville, FL, 3Universidad Pontificia Bolivariana, Medellín, Colombia, 4Mayo Clinic, Phoenix, AZ, 5Mayo Clinic Florida, Jacksonville, 6Mayo Clinic Hospital, Jacksonville, FL

    Background/Purpose: Anti-synthetase syndrome (ASyS) is a rare, heterogeneous inflammatory myopathy characterized by presence of anti-aminoacyl transfer RNA synthetase autoantibodies with multisystem disease manifestations including myositis,…
  • Abstract Number: 0519 • ACR Convergence 2025

    A Multi-criterion Feature Integration Framework for Accurate Diagnosis of Primary Sjögren’s Syndrome Using Routine Laboratory Tests: A Multicentre, Retrospective Cohort study

    Shu Liu1, Guanhao Wu1, Mengge Pan1, Qi Sun2, Jingchen Gao1, Xianming Long3, Chaogui Tang4, Xinran Yuan1 and Lingyun Sun1, 1Department of Rheumatology and Immunology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China (People's Republic), 2Department of Endocrinology and Metabolism, Affiliated Hospital of Nantong University, Nantong, China, Nantong, China (People's Republic), 3The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, China (People's Republic), 4The Affiliated Huaian First People’s Hospital of Nanjing Medical University, Huai’an First People’s Hospital, Nanjing Medical University, Huaian, China (People's Republic)

    Background/Purpose: Primary Sjögren's syndrome (pSS) is a prevalent systemic autoimmune disorder. However, the early and accurate diagnosis of pSS remains challenging due to its non-specific…
  • Abstract Number: 0659 • ACR Convergence 2025

    Human papillomavirus infection and systemic lupus erythematosus under biologic therapy: a retrospective analysis in a multicenter cohort

    Ivette Casafont-Solé1, Judit Font-Urgelles1, Iñigo Rúa-Figueroa2, Andrea Hernández-martín3, Tarek Salman Montes4, Marta De la Rubia Navarro5, Maria Piqueras García6, Sandra Garrote Corral7, EVA GLORIA TOMERO MURIEL8, Elena De la Mata Pinilla9, Belén Álvarez Rodríguez10, Julia Martínez Barrio11, José Gomez-Puerta12, Paola Vidal-Montal13, Eleonora Penzo14, Consuelo Ramos Giraldez15, Francisco Javier Novoa16, Vicenç Torrente-Segarra17, Jorge Juan Fragío Gil18, Leyre Riancho19 and Irene Altabás-González20, 1Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 2Hospital de Gran Canaria Doctor Negrin, Las Palmas GC, Spain, 3Hospital Universitario de Gran Canaria Dr Negrín, Las palmas, Spain, 4Hospital del Mar/Parc de Salut Mar-IMIM, Barcelona, Spain, 5Hospital de La Fe, Valencia, 6Servicio Murciano de Salud, Murcia, Spain, 7Hospital Ramón y Cajal, Madrid, 8Hospital Universitario de la Princesa, Madrid, Spain, 9Hospital 12 de Octubre, Madrid, 10Hospital de Áraba, áraba, Spain, 11Department of Rheumatology, Hospital Gregorio Marañón, Madrid, Spain, Madrid, Madrid, Spain, 12Rheumatology Department, Hospital Clinic, Barcelona, Spain, Barcelona, Spain, 13Rheumatology. Hospital Universitari de Bellvitge, Barcelona, Catalonia, Spain, 14Hospital Vall d'Hebrón, Barcelona, Spain, 15Hospital Universitario Virgen de Valme, Servicio de Reumatología, Seville, Spain, 16Hospital Insular de Gran Canaria, Las palmas, 17Hospital Comarcal Alt Penedés Garraf, Vilafranca del Penedès, Spain, 18Hospital General Universitario, Valencia, Spain, 19Hospital de Sierrallana, Torrelavega, 20Complejo Hospitalario de Vigo, Vigo, Spain

    Background/Purpose: Human papillomavirus (HPV) is responsible for 99.7% of cervical neoplasms and is the fourth most common cancer among women worldwide. Patients with systemic lupus…
  • Abstract Number: 1173 • ACR Convergence 2025

    Prevalence of Coronary Artery Involvement in IgG4-Related Disease Detected by Non-Gated Cross-Sectional Imaging

    Matthew Charles Baker1, Lauren Taylor2, Haziq Siddiqi2, Jison Hong2 and Brian Pogatchnik2, 1Stanford University, Menlo Park, CA, 2Stanford University, Stanford, CA

    Background/Purpose: IgG4-related disease (IgG4-RD) classically presents with a mass or diffusely enlarged organ, but it also affects blood vessels of all sizes. Coronary artery involvement…
  • Abstract Number: 1489 • ACR Convergence 2025

    Impact of Menopause on Long-Term Outcomes in Patients with Systemic Lupus Erythematosus

    Lorena López, José Bretón and Luis Vilá, University of Puerto Rico Medical Sciences Campus, San Juan, PR

    Background/Purpose: Women of childbearing age are more prone to developing autoimmune diseases, suggesting a role for sex hormones, particularly estrogens, in regulating both cellular and…
  • Abstract Number: 1670 • ACR Convergence 2025

    Large Retrospective Cohort Study Of Chronic Recurrent Multifocal Osteomyelitis: Disease Presentation, Clinical, And Laboratory Features

    Shima Yasin1, Shima Yasin2 and Polly Ferguson3, 1King Abdullah Specialized Children’s Hospital,Ministry of National Guard Health Affairs, Jeddah, Saudi Arabia, 2Univeristy of Iowa, Iowa City, 3University of Iowa Carver College of Medicine, Iowa City, IA

    Background/Purpose: Chronic recurrent multifocal osteomyelitis (CRMO) is an autoinflammatory bone disease that affects children and adolescents. The disease typically presents with bone pain with or…
  • Abstract Number: 2028 • ACR Convergence 2025

    Behçet’s Syndrome Beyond Endemic Borders: A 24-Year Longitudinal Analysis of Mortality in a Diverse South American Cohort

    Fabio Specian1, Carolina Ejnisman2, Rafael Bassara Macedo1, Pedro Araujo3, Barbara Bayeh2, Thiago Freitas4, Rafael Cordeiro5 and Henrique Giardini4, 1Rheumatology Division, Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo (USP), Sao Paulo, Sao Paulo, Brazil, 2Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, 3Universidade de São Paulo, Sao Paulo, São Paulo, Brazil, 4Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, Brazil, 5Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, Sao Paulo, Brazil

    Background/Purpose: Behçet’s syndrome (BS) is a chronic, relapsing vasculitis that contributes substantially to morbidity and mortality, primarily due to vascular and neurological complications. Most of…
  • Abstract Number: 2302 • ACR Convergence 2025

    Clustering by ESSPRI and PROMIS domain measures defines distinct subtypes and facilitates longitudinal assessment of patients with Sjogren’s disease

    Thomas Grader-Beck1, Jennifer Reed2, Priya Patel3, Ji Soo Kim4 and Alan Baer5, 1Johns Hopkins, Reisterstown, MD, 2Johns Hopkins, Freeland, MD, 3Johns Hopkins, Annville, PA, 4Johns Hopkins, Baltimore, MD, 5Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Patient-reported outcomes (PROs) measure a patient’s health-related quality of life. The role of ESSPRI and PROMIS measures in identifying subsets of patients with Sjogren’s…
  • Abstract Number: 2503 • ACR Convergence 2025

    Validation of a Composite Biomarker Score To Predict Modified Rodnan Skin Score: Insight From Autologous Stem Cell Transplantation International Scleroderma trial

    stefano rodolfi1, kristina clark2, bahja Ahmed Abdi1, medha kanitkar3, Voon H. Ong3, Alexandre Voskuijl4, Jeska de Vries-Bouwstra5, Jacob M. van Laar6, Christopher Denton7 and julia Spierings8, 1University College London, London, United Kingdom, 2Kennedy Institute of Rheumatology, University of Oxford, London, United Kingdom, 3Division of Medicine, Centre for Rheumatology, University College London, London, United Kingdom, 4Amsterdam University Medical Center, Amsterdam, Netherlands, 5Leiden University Medical Center, Leiden, Netherlands, 6UMC Utrecht, Utrecht, Netherlands, 7University College London, UK, London, United Kingdom, 8Department of Rheumatology & Clinical Immunology, University Medical Center, Ultrecht, The Netherlands, Utrecht, Netherlands

    Background/Purpose: Skin fibrosis is a cardinal manifestation of diffuse cutaneous systemic sclerosis (dcSSc) and is routinely measured via the modified Rodnan skin score (mRSS); however,…
  • Abstract Number: 0305 • ACR Convergence 2025

    From Movement to Meaning: Exploring Physical Function in IBM with Actigraphy

    Vaidehi Kothari1, Eaman Alhassan2, Kevin Renz Ambrocio1, Bonny Rockette-Wagner3, Chester V. Oddis1, Kendrea (Focht) Garand1 and Rohit Aggarwal4, 1University of Pittsburgh, Pittsburgh, PA, 2University of Pittsburgh Medical Center, Pittsburgh, PA, 3University of Pittsburgh, PITTSBURGH, 4University of Pittsburgh, Rheumatology and Clinical Immunology, Pittsburgh, United States of America, Pittsburgh, PA

    Background/Purpose: Inclusion body myositis (IBM) is a progressive and severe inflammatory muscle disease that primarily affects adults over 50 years of age. It presents with…
  • Abstract Number: 0540 • ACR Convergence 2025

    Low-Dose CT reveals syndesmophyte progression in axial SpA, particularly in the thoracic spine: Insights from the SPACE cohort covering early and established disease

    Manouk de Hooge1, Mary Lucy Marques2, Gizem Ayan3, Miranda van Lunteren4, Liese de Bruin4, Monique Reijnierse5, Désirée Van Der Heijde4, Sofia Ramiro6 and Floris A. van Gaalen4, 1Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, 2Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands; and Coimbra Local Health Unit, Coimbra, Portugal, 3Ankara Research and Training Hospital, Ankara, Turkey, 4Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 5Department of Radiology, Leiden University Medical Center, Leiden, Netherlands, 6Leiden University Medical Center, Bunde, Netherlands

    Background/Purpose: Low-dose computed tomography (ldCT) has not previously been used to assess pt with axial spondyloarthritis (axSpA) early in their disease course, especially those with…
  • Abstract Number: 0691 • ACR Convergence 2025

    Association of Elevated Platelets and CRP With Severe Disease and Poor Survival in Systemic Sclerosis

    Brian Lee1, Shufeng Li1, Srijana Davuluri2, Jennifer Lee1 and Lorinda Chung2, 1Stanford University, Stanford, 2Stanford University, Stanford, CA

    Background/Purpose: Elevated acute phase reactants such as platelets and C-reactive protein (CRP) have been used as inclusion criteria to enrich systemic sclerosis (SSc) clinical trials…
  • Abstract Number: 1174 • ACR Convergence 2025

    High Prevalence of Autoimmunity in Rosai Dorfman Disease: A Multinational Study

    Mitali Sen1, Gordon Ruan2, Samuel Reynolds3, Haadi Ali3, Xi Yang3, Diana Morlote1, Aishwarya Ravindran1, Lauren Shea1, Matthew Koster4, Jithma Abeykoon2, Hind Salama5, Xin-Xin Cao6, Asra Ahmed3, Ronald Go2 and Gaurav Goyal1, 1University of Alabama at Birmingham, Birmingham, AL, 2Mayo Clinic, Rochester, 3University of Michigan, Michigan, 4Mayo Clinic, Rochester, MN, 5National Guard Health Affairs, Riyadh, Saudi Arabia, 6Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China (People's Republic)

    Background/Purpose: Rosai-Dorfman Disease (RDD), formerly known as sinus histiocytosis with massive lymphadenopathy, was initially thought to be inflammatory or autoimmune in nature. The discovery of…
  • Abstract Number: 1491 • ACR Convergence 2025

    Feasibility of Extrarenal Systemic Lupus Erythematosus Disease Modification in GLADEL 2.0, a Latin American Cohort

    julián Barahona-correa1, Santiago Bernal-Macías2, Daniel Fernandez3, Óscar Muñoz2, Lucia Hernández4, Erika Susana Palacios Santillan5, Laura Maurelli6, Paula Alba7, Veronica Saurit8, Lucila Garcia9, María Emilia Sattler10, Maria Constanza Bertolaccini11, Marina Laura Micelli12, Graciela Gomez13, Micaela A. Cosatti14, Ana Carolina Ralle15, Joaquín Martinez Serventi16, Ana Silva17, ODIRLEI MONTICIELO18, Ángela Luzia Branco Pinto Duarte19, Laíssa Cristina Alves Alvino20, Eduardo Borba21, Eloisa Bonfa21, Edgard dos Reis-Neto22, Iris Guerra Herrera23, Milena Mimica24, Gustavo Aroca Martínez25, Lorena Gómez Escorcia26, Carlos Alberto Cañas27, Gerardo Quintana-Lopez28, Carlos Toro-Gutierrez29, José Maximiliano Martínez Pérez30, Reyna Elizabeth Sánchez-Briones31, Mario Pérez Cristóbal32, Eduardo Martin-Nares33, Yaneli Juarez-Vicuña34, Ignacio García-Valladares35, Rodrigo Ortiz Hernández36, Jorge Antonio Esquivel Valerio37, Maria Isabel Acosta38, Astrid Paats39, Jorge Cieza Calderón40, Manuel Ugarte-Gil41, Armando Calvo42, Rodamin Ambiorix Alvarez Santana43, Analía Cánepa44, Carina Pizzarossa44, Federico Zazzetti45, Ashley Orillion46 and Cristina Drenkard47, 1Colombian Association of Rheumatology (ASOREUMA), Bogotá, Colombia; Hospital Universitario San Ignacio, Bogotá, Colombia, Bogotá, Colombia, 2Hospital Universitario San Ignacio, Bogotá, Colombia, Bogotá, Colombia, 3Facultad de Medicina, Pontificia Universidad Javeriana, Bogotá, Colombia; Departamento de Medicina Interna, Unidad de Reumatología, Hospital Universitario San Ignacio, Bogotá, Colombia, BOGOTA, Colombia, 4Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, Rosario, Argentina, 5Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, Buenos Aires, Argentina, 6Hospital Italiano de Córdoba, Córdoba, Argentina, Córdoba, Argentina, 7Hospital Córdoba y Sanatorio Allende, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Córdoba, Argentina, Cordoba, Argentina, 8Hospital Privado Universitario de Cordoba, Córdoba, Argentina, Córdoba, Argentina, 9Hospital San Martin de La Plata, La Plata, Argentina, La Plata, Argentina, 10Sanatorio Británico, Rosario, Argentina, Rosario, Argentina, 11Hospital Ángel C. Padilla, Tucumán, Argentina, Tucumán, Argentina, 12Hospital J.M Ramos Mejía, Buenos Aires, Argentina, Buenos Aires, 13Instituto de Investigaciones Médicas Alfredo Lanari, Universidad de Buenos Aires, Buenos Aires, Argentina, Buenos Aires, Argentina, 14CEMIC Centro de Educación Médica e Investigaciones Clínicas ‘‘Norberto Quirno,’’ Buenos Aires, Argentina, Buenos Aires, Argentina, 15Hospital Señor del Milagro Salta, Salta, Argentina, Salta, Argentina, 16Hospital General de Agudos Dr. Juan A. Fernández, Buenos Aires, Argentina, Buenos Aires, Argentina, 17Hospital das Clinicas da Universidade Federal de Goias, Goiania, Brazil, Goiania, Brazil, 18Hospital de Clínicas de Porto Alegre, Universidade Federal Do Rio Grande Do Sul, Porto Alegre, Brazil, PORTO ALEGRE, Rio Grande do Sul, Brazil, 19Universidad Federal de Pernambuco, Recife, Brazil, Recife, Brazil, 20Hospital Universitário Pedro Ernesto - Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, Rio de Janeiro, Brazil, 21Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil, 22Escola Paulista de Medicina / Universidade federal de São Paulo (EPM / Unifesp), São Paulo, Brazil, São Paulo, Brazil, 23Hospital del Salvador Santiago de Chile, Santiago, Chile, Santiago, Chile, 24Facultad de Medicina y Ciencia, Universidad San Sebastián, Santiago, Chile, Santiago, Chile, 25Universidad Simón Bolívar, Barranquilla, Colombia y Clínica de la Costa, Barranquilla, Colombia, 26Clínica de la Costa y Universidad Simón Bolívar Barranquilla, Barranquilla, Colombia, Barranquilla, Colombia, 27Fundación Valle del Lili, Universidad Icesi, Cali, Colombia, Cali, Colombia, 28Facultad de Medicina, Universidad Nacional de Colombia; Hospital Universitario Fundación Santa Fe de Bogotá; Hospital Universitario Nacional de Colombia, Bogotá, Colombia, Bogotá, Colombia, 29Pontificia Universidad Javeriana de Cali, Cali, Colombia, Cali, Colombia, 30Universidad de Especialidades Espíritu Santo, Guayaquil, Ecuador, Guayaquil, Ecuador, 31Hospital de Especialidades Dr. Antonio Fraga Mouret, Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, Mexico City, Mexico, Mexico City, Mexico, 32Hospital de Especialidades del Centro Médico Nacional SXXI, Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico, Mexico City, Mexico, 33Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico City, Mexico, 34Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, Mexico City, Mexico, 35Centro de Estudios de Investigación Básica y Clínica, S.C., Guadalajara, Mexico, Guadalajara, Mexico, 36Facultad de Medicina de la Universidad Autónoma de San Luis Potosí y Hospital Central "Dr. Ignacio Morones Prieto," San Luis Potosi, Mexico, San Luis Potosi, Mexico, 37Universidad Autónoma de Nuevo León, Rheumatology Service, Hospital Universitario "Dr. José Eleuterio González", Monterrey, Nuevo León, México., MONTERREY, Mexico, 38Facultad de Ciencias Medicas, Universidad Nacional de Asunción, San Lorenzo, Paraguay, Asuncion, Paraguay, 39Facultad de Ciencias Medicas, Universidad Nacional de Asunción, San Lorenzo, Paraguay, Asunción, Paraguay, 40Hospital Nacional Edgardo Rebagliati Martins-EsSalud, Lima, Peru, Lima, Peru, 41Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Peru; Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, Lima, Peru, 42Hospital Nacional Cayetano Heredia Universidad Peruana Cayetano Heredia, Lima, Peru, Jesús María, Peru, 43Hospital Docente Padre Billini, Santo Domingo, Distrito Nacional, Dominican Republic, 44Hospital de Clínicas, Facultad de Medicina, UDELAR, Montevideo, Uruguay, Montevideo, Uruguay, 45Johnson & Johnson, Horsham, PA, USA, Ambler, PA, 46Johnson & Johnson, Spring House, PA, USA, Spring House, PA, 47Rollins School of Public Health, Emory University, Atlanta, Georgia, USA, Acworth, GA

    Background/Purpose: The concept of disease modification (DM) has been recently introduced to improve the long-term care of patients (pts) with SLE. DM is defined as…
  • 1
  • 2
  • 3
  • …
  • 38
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology